On Tuesday US Health Secretary Alex Azar said that if Pfizer submits the positive initial data from its COVID-19 vaccine trial to health regulators as quickly as expected, the U.S. government plans to begin vaccinating Americans in December.
Upon FDA authorization, the United States would receive about 20 million doses of the Pfizer vaccine per month, Azar said on a call with reporters, noting that HHS could being procuring supplies at the end of this month.
The United States has a $1.95 billion contract for 100 million doses of the Pfizer vaccine – enough to inoculate 50 million people – with an option to acquire 500 million more.
Earlier on Tuesday, Azar said on CNBC that final decisions are subject to a close look at the vaccine efficacy data.
Based on recommendations to the government, it will likely start with inoculations of the elderly in nursing homes and assisted living facilities, healthcare workers and first responders, with a goal to complete those shots by the end of January.
Azar said he anticipates there will soon be more vaccines to protect against COVID-19 from other companies, including Moderna, which is expected to announce interim results of a large trial of its experimental vaccine at the end of the month.
Azar told CBNC: “By the end of March, early April, we expect to have enough for every American who would like to be vaccinated.”
On Monday, Pfizer on Monday said the vaccine it has been developing with German partner BioNTech SE was 90% effective against COVID-19, based on an early look at results from its large, late-stage trial.
The U.S. drugmaker said it expects to have safety data as soon as next week that it needs to apply for emergency use authorization (EUA) with the U.S. Food and Drug Administration.
